位置:首页 > 产品库 > CM-272
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CM-272
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CM-272图片
CAS NO:1846570-31-7

CM-272 是一种首创的,有效的,选择性的,底物竞争性的且可逆的双重G9a/DNA 甲基转移酶 (DNMTs) 抑制剂。CM-272 具有抗肿瘤活性。CM-272 抑制G9aDNMT1DNMT3ADNMT3BGLPIC50分别为 8 nM,382 nM,85 nM,1200 nM 和 2 nM。CM-272 抑制细胞增殖并促进细胞凋亡,诱导干扰素刺激的基因和免疫原性细胞死亡。
生物活性

CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dualG9a/DNA methyltransferases (DNMTs)inhibitor with antitumor activities. CM-272 inhibitsG9a,DNMT1,DNMT3A,DNMT3BandGLPwithIC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotesapoptosis, inducing IFN-stimulated genes and immunogenic cell death[1].

IC50& Target[1]

G9a

8 nM (IC50)

DNMT1

382 nM (IC50)

DNMT3A

85 nM (IC50)

DNMT3B

1200 nM (IC50)

体外研究
(In Vitro)

CM-272 (100-1000 nM; 12-72 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment inhibits cell proliferation in a dose- and time-dependent manner[1].
CM-272 (100-1000 nM; 24 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment blocks cell cycle progression[1].
CM-272 (100-1000 nM; 12-72 hours; CEMO-1, MV4-11 and OCI-Ly10 cell lines) treatment induces apoptosis in ALL, AML and DLBCL cell lines in a dose- and time-dependent manner[1].
CM-272 after 48 h of treatment CEMO-1 acute lymphoblastic leukaemia (ALL) cell line, MV4-11 acute myeloid leukaemia (AML) cell line and OCI-Ly10 diffuse large B-cell lymphoma (DLBCL) cell line, the GI50values of 218 nM, 269 nM and 455 nM, respectively, and is associated with a decrease in global levels of H3K9me2 and 5mC[1].
The therapeutic activity of CM-272 relies on the early activation of the type I IFN response in tumour cells, potentially leading to the induction of cell autonomous immunogenic death in tumour cells[1].

Cell Proliferation Assay[1]

Cell Line:CEMO-1, MV4-11 and OCI-Ly10 cell lines
Concentration:125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells)
Incubation Time:12 hours, 24 hours, 48 hours and 72 hours
Result:Inhibited cell proliferation in a dose- and time-dependent manner.

Cell Cycle Analysis[1]

Cell Line:CEMO-1, MV4-11 and OCI-Ly10 cell lines
Concentration:125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells)
Incubation Time:24 hours
Result:Blocked cell cycle progression.

Apoptosis Analysis[1]

Cell Line:CEMO-1, MV4-11 and OCI-Ly10 cell lines
Concentration:125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells)
Incubation Time:12 hours, 24 hours, 48 hours and 72 hours
Result:Induced apoptosis in ALL, AML and DLBCL cell lines in a dose- and time-dependent manner.
体内研究
(In Vivo)

CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2–/–γc–/–mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models[1].

Animal Model:Female BALB/Ca-Rag2–/–γc–/–mice (6–8-week-old) with CEMO-1 cells[1]
Dosage:2.5 mg/kg
Administration:Intravenous injection; daily; for 28 days
Result:Induced a statistically significant increase in overall survival (OS) in mice.
分子量

478.63

性状

Solid

Formula

C28H38N4O3

CAS 号

1846570-31-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL(261.16 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.0893 mL10.4465 mL20.8930 mL
5 mM0.4179 mL2.0893 mL4.1786 mL
10 mM0.2089 mL1.0446 mL2.0893 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.08 mg/mL (4.35 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.35 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在本网站选购。
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024